Published in J Exp Clin Cancer Res on December 01, 2004
Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med (2011) 2.21
Peroxisome proliferator-activated receptor gamma-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res (2008) 1.09
Characterization of heparin-binding site of tissue transglutaminase: its importance in cell surface targeting, matrix deposition, and cell signaling. J Biol Chem (2012) 1.00
Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors. BMC Cancer (2008) 0.98
Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochim Biophys Acta (2015) 0.92
Cellular apoptosis susceptibility (CSE1L/CAS) protein in cancer metastasis and chemotherapeutic drug-induced apoptosis. J Exp Clin Cancer Res (2010) 0.83
Intracellular redox status controls membrane localization of pro- and anti-migratory signaling molecules. Redox Biol (2014) 0.82
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine. Oncotarget (2015) 0.76
Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival. Singapore Med J (2014) 0.75
Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer (2003) 4.22
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
Rectal metastases from lobular carcinoma of the breast: report of a case and literature review. Ann Oncol (2001) 2.23
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.84
Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer (2002) 1.68
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer (1996) 1.58
Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.52
Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev (2012) 1.42
Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol (2010) 1.40
Endometrioid carcinoma of the prostate. The diagnostic value of Leu7 and prostatic specific antigen. Br J Urol (1993) 1.38
Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol (2000) 1.31
Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG) Br J Cancer (1994) 1.30
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol (2009) 1.27
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer (2003) 1.24
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer (2007) 1.23
Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.23
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer (2010) 1.14
Vitrectomy results for diffuse diabetic macular edema with and without inner limiting membrane removal. Eur J Ophthalmol (2004) 1.13
Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer (1994) 1.13
Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. Eye (Lond) (2006) 1.12
Human malignant tumours of the breast, as compared to their respective normal tissue, have elevated expression of the Harvey ras oncogene. Anticancer Res (1984) 1.12
Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiologic, histologic, and clinical features. Lung Cancer (2004) 1.12
The presence of proprioceptive mechanoreceptors in the remnants of the ruptured ACL as a possible source of re-innervation of the ACL autograft. Knee Surg Sports Traumatol Arthrosc (2001) 1.11
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol (2005) 1.10
The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol (2011) 1.10
Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur J Cancer (2000) 1.08
Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist (2001) 1.07
Patients with multiple myeloma and solid tumors: six case reports. J Exp Clin Cancer Res (1998) 1.07
Updated diagnostic criteria for partial and complete hydatidiform moles in early pregnancy. Anticancer Res (2003) 1.02
Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: biases and evolution over time. Eur J Cancer (2003) 1.02
p63 expression in benign and malignant breast lesions. Histol Histopathol (2004) 1.01
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol (2005) 1.00
Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study. Oncology (1998) 1.00
A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin. Anticancer Res (2008) 0.99
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer (2008) 0.99
Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol (1994) 0.99
Eosinophilic gastroenteritis: presentation of two patients with unusual affect of terminal ileum and caecum with manifestations of acute abdomen and literature review. Int J Clin Pract (2004) 0.99
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. Ann Oncol (2011) 0.99
NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer (2012) 0.98
Cancer and pregnancy: a comprehensive review. Surg Oncol (2011) 0.97
The missing kiss of life: transcriptional activity of the metastasis suppressor gene KiSS1 in early breast cancer. Anticancer Res (2007) 0.96
Immunohistochemical expression of superoxide dismutase (MnSOD) anti-oxidant enzyme in invasive breast carcinoma. Histol Histopathol (2004) 0.96
The MAPK-AP-1/-Runx2 signalling axes are implicated in chondrosarcoma pathobiology either independently or via up-regulation of VEGF. Histopathology (2005) 0.96
Cancer, fertility and pregnancy: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 0.96
NT5E CpG island methylation is a favourable breast cancer biomarker. Br J Cancer (2012) 0.96
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol (2005) 0.95
Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas. Mod Pathol (2003) 0.95
Immunohistochemical study of angiogenesis and proliferative activity in epiretinal membranes. Int J Clin Pract (2005) 0.95
Primary extranodal non-Hodgkin's lymphoma of the head and neck. Oncology (1992) 0.94
Thyroid disease in Sjögren's syndrome. Arthritis Rheum (1980) 0.94
hMSH2 is the most commonly mutated MMR gene in a cohort of Greek HNPCC patients. Br J Cancer (2005) 0.94
Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol (2008) 0.93
Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. Br J Cancer (2007) 0.93
Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. BMC Cancer (2006) 0.93
Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev (2008) 0.93
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J (2011) 0.92
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat (2008) 0.91
Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol (2007) 0.91
Lung cancer in pregnancy: report of nine cases from an international collaborative study. Lung Cancer (2013) 0.90
Heterogeneity in cancer guidelines: should we eradicate or tolerate? Ann Oncol (2008) 0.90
Renal cell carcinoma in pregnancy: a rare coexistence. Clin Transl Oncol (2013) 0.89
Lung, pleural and colon actinomycosis in an immunocompromised patient: a rare form of presentation. Chemotherapy (2003) 0.89
Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group. J Clin Oncol (1996) 0.89
Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Cancer Chemother Pharmacol (2012) 0.89
Stress-induced impairment of macrophage tumoricidal function. Psychosom Med (1980) 0.88
Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study. Oncology (1998) 0.88
Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety. Med Oncol (2006) 0.88
Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group. Br J Cancer (1996) 0.88
Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. Int J Gynecol Cancer (2007) 0.88
Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma. Int J Gynecol Cancer (2006) 0.88
Immunohistochemical expression of p53, p21/waf1, rb, p16, cyclin D1, p27, Ki67, cyclin A, cyclin B1, bcl2, bax and bak proteins and apoptotic index in normal thymus. Histol Histopathol (2001) 0.88
Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas. Histol Histopathol (2004) 0.87
Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study. Gynecol Oncol (1998) 0.87
CD44 family and gynaecological cancer. In Vivo (2004) 0.87
Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data. Anticancer Res (2006) 0.87
CD44 standard form expression as a predictor of progression in high risk superficial bladder tumors. Int Urol Nephrol (2001) 0.87
Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. Eur J Cancer (2003) 0.87
Immunohistochemical study of extracellular matrix components in epiretinal membranes of vitreoproliferative retinopathy and proliferative diabetic retinopathy. Eur J Ophthalmol (2005) 0.86
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 0.86